Under: Fat Loss
Best Peptides for Insulin Resistance
Reduced cellular response to insulin, impairing glucose uptake and promoting fat storage.
Insulin resistance occurs when cells fail to respond appropriately to insulin signaling, leading to impaired glucose uptake and increased fat storage. Research peptides such as semaglutide and tirzepatide are being studied for their mechanisms in modulating insulin secretion and metabolic pathways—semaglutide through GLP-1 receptor activation and tirzepatide through dual GIP/GLP-1 receptor activation. These peptides are investigated for their potential effects on glucose homeostasis and metabolic markers associated with insulin resistance.
Research peptide protocols for insulin resistance typically involve subcutaneous administration on a weekly or daily schedule, depending on the specific peptide and study design. Dosing frequently follows a titration approach, beginning at lower concentrations and incrementally increasing to assess tolerability and metabolic response, with monitoring of glucose levels and metabolic markers recommended throughout any research protocol.
Peptides Studied for Insulin Resistance
| Peptide | Evidence | Notes | Actions |
|---|---|---|---|
| Retatrutide Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied. | high | — | |
| Retatrutide Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied. | high | — | |
| Semaglutide Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide. | high | — | |
| Semaglutide Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide. | high | — | |
| Tirzepatide Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials. | high | — | |
| Tirzepatide Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials. | high | — |
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.